[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Fate Therapeutics (FATE)

Fate Therapeutics (FATE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 220,936
  • Shares Outstanding, K 116,282
  • Annual Sales, $ 6,650 K
  • Annual Income, $ -136,320 K
  • EBIT $ -148 M
  • EBITDA $ -138 M
  • 60-Month Beta 2.13
  • Price/Sales 37.36
  • Price/Cash Flow N/A
  • Price/Book 1.19

Options Overview Details

View History
  • Implied Volatility 187.99% (+55.30%)
  • Historical Volatility 127.83%
  • IV Percentile 35%
  • IV Rank 9.05%
  • IV High 1,257.44% on 11/18/25
  • IV Low 81.57% on 06/04/25
  • Expected Move (DTE 34) 0.7225 (40.57%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 780
  • Volume Avg (30-Day) 747
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 10,770
  • Open Int (30-Day) 9,040
  • Expected Range 1.0584 to 2.5034

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.30
  • Number of Estimates 5
  • High Estimate $-0.29
  • Low Estimate $-0.32
  • Prior Year $-0.29
  • Growth Rate Est. (year over year) -3.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2200 +44.26%
on 04/30/26
2.4650 -28.60%
on 05/08/26
+0.4700 (+36.43%)
since 04/15/26
3-Month
1.0400 +69.23%
on 03/19/26
2.4650 -28.60%
on 05/08/26
+0.5100 (+40.80%)
since 02/13/26
52-Week
0.9100 +93.41%
on 08/11/25
2.4650 -28.60%
on 05/08/26
+0.7500 (+74.26%)
since 05/15/25

Most Recent Stories

More News
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase

EQNX::TICKER_START (NASDAQ:GTBP),(NASDAQ:ARTV),(NASDAQ:FATE),(NASDAQ:IBRX),(NASDAQ:CHRS) EQNX::TICKER_END

CHRS : 1.5800 (-3.07%)
GTBP : 0.3969 (-9.57%)
FATE : 1.7400 (-8.42%)
ARTV : 9.85 (-7.77%)
IBRX : 8.05 (-1.23%)
Fate Therapeutics: Q1 Earnings Snapshot

Fate Therapeutics: Q1 Earnings Snapshot

FATE : 1.7400 (-8.42%)
Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

RECLAIM – LN, a Phase 2 potentially registrational clinical trial of FT819 in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis, on schedule to initiate...

FATE : 1.7400 (-8.42%)
Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting

Single dose treatment of FT819 without conditioning chemotherapy achieves lupus low disease activity state (LLDAS) in active SLE Patients; durable B cell remodeling is exhibited by depletion of major B...

FATE : 1.7400 (-8.42%)
Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819

FDA Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program supports the acceleration of manufacturing readiness for therapies with expedited clinical development timelines...

FATE : 1.7400 (-8.42%)
Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem...

FATE : 1.7400 (-8.42%)
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, May 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem...

FATE : 1.7400 (-8.42%)
Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting

SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent...

FATE : 1.7400 (-8.42%)
Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the...

SAN DIEGO, April 16, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent...

FATE : 1.7400 (-8.42%)
Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences

SAN DIEGO, April 09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent...

FATE : 1.7400 (-8.42%)

Business Summary

Fate Therapeutics is a clinical-stage biopharmaceutical company, which is focused on the development of programmed cellular immunotherapies for cancer and immune disorders.' The company uses various therapeutic approaches for cell programming to develop cell therapies. The company programs cells of the...

See More

Key Turning Points

3rd Resistance Point 2.4000
2nd Resistance Point 2.3000
1st Resistance Point 2.1000
Last Price 1.7400
1st Support Level 1.8000
2nd Support Level 1.7000
3rd Support Level 1.5000

See More

52-Week High 2.4650
Fibonacci 61.8% 1.8710
Last Price 1.7400
Fibonacci 50% 1.6875
Fibonacci 38.2% 1.5040
52-Week Low 0.9100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.